FTC approves Endo’s $8bn buyout of Par

The Federal Trade Commission (FTC) has issued a final approval of Endo’s $8 billion acquisition of Par Pharmaceutical, saying it is not anti-competitive.

The FTC voted 4-0 to approve the deal on November 10 following the closure of a public comment period.

One of the requirements for the deal was for Endo to divest its rights to market generic glycopyrrolate tablets, which are used to treat ulcers, and generic methimazole tablets, used to curb the excess production of thyroid hormones.

The deal was first approved by the FTC in September, but the organisation invited the general public to comment on any potential issues around the merger. The comment period ended on October 28.